Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone receptor-positive metastatic breast cancer patients

Cancer Biology and Therapy

Volumn 8, Issue 15, 2009, Pages 1450-1455

  Camerini, Andrea ^a,c   Rondini, Marianna ^a   Garrone, Ornella ^b   Valsuani, Chiara ^a   Donati, Sara ^a   Siclari, Olimpia ^a   Sgambato, Alessandro ^c   Tartarelli, Gianna ^a   Vincenti, Maura ^d   Mattiot, Valentina Polla ^b   Porta, Romana Prosperi ^e   Puccetti, Cheti ^a   Puccinelli, Paolo ^a   Amoroso, Domenico ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b S CROCE E CARLE HOSPITAL   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d OSPEDALE DEGLI INFERMI   (Italy)

^e UNIVERSITY OF PISA   (Italy)

Author keywords

Advanced breast cancer; Coagulation; Endometrial mucosa; Fulvestrant; Hormonal treatment; Lipids; Progesterone

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; CHOLESTEROL; DRUG DERIVATIVE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROGESTERONE; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIACYLGLYCEROL; TUMOR PROTEIN;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; BREAST TUMOR; CLINICAL TRIAL; DRUG EFFECT; ENDOMETRIUM; FEMALE; HUMAN; LIPID METABOLISM; METASTASIS; MIDDLE AGED; NEOPLASM; PATHOLOGY; PHYSIOLOGY; POSTMENOPAUSE; PROSPECTIVE STUDY; ULTRASTRUCTURE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHOLESTEROL; CHOLESTEROL, LDL; ENDOMETRIUM; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; HUMANS; LIPID METABOLISM; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; PROGESTERONE; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIGLYCERIDES;

EID: 85046915150     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.15.8959     Document Type: Article

References (27)

1. Bross PF, Cohen MH, Williams GA, Pazdur R. FDA drug approval summaries: Fulvestrant. The Oncologist 2002; 7:477-480 (Pubitemid 36008996)
2. Wakeling AE, Dukes M, Boiler J. A potent specific pure anti-estrogen with clinical potential. Cancer Res 1991; 51:3867-3873
3. Levesque C, Merand Y, Dufour Jm, Labrie C, Labrie F. Synthesis and biological activity of new halosteroidal anti-estrogens. J Med Chem 1991; 34:1624-1630
4. Pink JJ, Jordan VC. Models of estrogen receptor regulation by estrogen and anti-estrogen in breast cancer cell lines. Cancer Res 1996; 56:2321-2330 (Pubitemid 26154081)
5. Parker MG. Action of "pure" anti-estrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 1993; 26:131-137
6. Wakeling AE. Use of pure anti-estrogens to elucidate the mode of action of estrogens. Biochem Pharmacol 1995; 49:1545-1549
7. Robertson JFR, Nicholson I, Bundred NJ, Anderson E, Rayter Z, Dowsett M, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5- pentafluoropentylsulfinyl)-nonyl] estra-1,3,5,(10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001; 61:6739-6746
8. Dukes M, Miller D, Wakeling AE, et al. Antiuterotrophic effects of a pure antiestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys. J Endocrinol 1993; 138:203-209
9. Howell A, Robertson JFR, Quaresima Albano J, Aschermannova A, Mauriac L, Kleeberg UR, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20:3396-3403
10. Osborne CK, Pippen J, Jones Se, Parker LM, Ellis M, Come S, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine treatment: results of a North American trial. J Clin Oncol 2002; 20:3386-3395 (Pubitemid 34894671)
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
12. Von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17:237-246
13. Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New Engl J Med 2005; 353:2747-2757 (Pubitemid 43016814)
14. Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005; 26:5126-5137 (Pubitemid 46224021)
15. Banerjee S, Smith IE, Folkerd L, Iqbal J, Barker P, Dowsett M, for IMPACT trialists. Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. Ann Oncol 2005; 16:1632-1638
16. Wojtacki J, Lesniewski-Kmak K, Pawlack W. Anastrozole therapy and lipid profile: an update. Eur J Cancer 2004; 2:142.
17. Conte P, Frassodati A. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: putting safety issues into perspective. Breast J 2007; 13:28-35. (Pubitemid 46046490)
18. Tisdale MJ. Wasting in cancer. J Nutr 1999; 129:243-246
19. Wu J, Liang Y, Nawaz Z, Hyder SM. Complex agonist-like properties of ICI 182,780 (Faslodex) in human breast cancer cells that predominantly express progesterone receptor-B: implication for treatment resistance. Int J Oncol 2005; 27:1647-1659
20. Wu J, Richer J, Horwitz KB, Hyder SM. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B. Cancer Res 2004; 64:2238-2244 (Pubitemid 38339478)
21. Liang Y, Brekken RA, Hyder SM. Vascular endothelial growth factor induces proliferation of the breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr Relat Cancer 2006; 13:905-919 (Pubitemid 44763266)
22. Gimpl G, Wiegand V, Burger K, Fahrenholz F. Cholesterol and steroid hormones: modulators of oxytocin receptor function. Prog Brain Res 2002; 139:43-55. (Pubitemid 35460879)
23. Gallagher A, Chambers TJ, Tobias JH. The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats. Endocrinology 1993; 133:2787-2791 (Pubitemid 24000737)
24. Sibonga JD, Dobnig H, Harden RM, Turner RT. Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia. Endocrinology 1998; 139:3736-3742 (Pubitemid 28512252)
25. Evans GL, Bryant HU, Magee DE, Turner RT. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 1996; 134:2283-2288
26. Imenez MA, Magee DE, Bryant HU, Turner RT. Clomiphene prevents cancellous bone loss from tibia of ovariectomized rats. Endocrinology 1997; 138:1794-1800 (Pubitemid 27180791)
27. Lewis S. Do endocrine treatment for breast cancer have a negative impacy on lipid profiles and cardiovascular risk in postmenopausal women?. Am Heart J 2007; 153:182-188 (Pubitemid 46096865)